NCT06948331View on ClinicalTrials.gov

RADA16 for Aquablation Day Case

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

August 1, 2025

Study Completion Date

September 1, 2025

Conditions
HematuriaBenign Prostatic HyperplasiaLower Urinary Tract Symptoms
Interventions
DEVICE

PuraStat

Sterile gel composed of synthetic peptide and sterile water; provided as a prefilled syringe. The will be applied to the inside of the prostate to help stop bleeding following Aquablation.

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER